CELL SEARCH SYSTEM -CELL BANK- (RIKEN BRC) [RCB0035 : WEHI-3]

922 Almeida JL, Dakic A, Kindig K, Kone M, Letham DLD, Langdon S, Peat R, Holding-Pillai J, Hall EM, Ladd M, Shaffer MD, Berg H, Li J, Wigger G, Lund S, Steffen CR, Fransway BB, Geraghty B, Natoli M, Bauer B, Gollin SM, Lewis DW, Reid Y. Interlaboratory study to validate a STR profiling method for intraspecies identification of mouse cell lines PLoS One 2019 14(6):e0218412 PubMed ID: 31220119 DOI: 10.1371/journal.pone.0218412

143 Walker EB, Lanier LL, Warner NL. Concomitant induction of the cell surface expression of Ia determinants and accessory cell function by a murine macrophage tumor cell line J Exp Med 1982 155(2):629-34 PubMed ID: 6173461 DOI: 10.1084/jem.155.2.629

92 Walker EB, Lanier LL, Warner NL. Characterization and functional properties of tumor cell lines in accessory cell replacement assays J Immunol 1982 128(2):852-9 PubMed ID: 7033383

5287 McKean DJ, Infante AJ, Nilson A, Kimoto M, Fathman CG, Walker E, Warner N. Major histocompatibility complex-restricted antigen presentation to antigen-reactive T cells by B lymphocyte tumor cells. J Exp Med 1981 154(5):1419-31 PubMed ID: 6170720 DOI: 10.1084/jem.154.5.1419

17 Baca OG, Akporiaye ET, Aragon AS, Martinez IL, Robles MV, Warner NL. Fate of phase I and phase II Coxiella burnetii in several macrophage-like tumor cell lines Infect Immun 1981 33(1):258-66 PubMed ID: 7263063 DOI: 10.1128/iai.33.1.258-266.1981

980 Metcalf D Clonal extinction of myelomonocytic leukemic cells by serum from mice injected with endotoxin. Int J Cancer 1980 25:225-33 PubMed ID: 6967053 DOI: 10.1002/ijc.2910250210

1294 Ralph P, Nakoinz I Direct toxic effects of immunopotentiators on monocytic, myelomonocytic, and histiocytic or macrophage tumor cells in culture. Cancer Res 1977 37:546-50 PubMed ID: 318922

716 Ralph P, Nakoinz I Antibody-dependent killing of erythrocyte and tumor targets by macrophage-related cell lines: enhancement by PPD and LPS. J Immunol 1977 119:950-54 PubMed ID: 894031

1141 Ralph P, Moore, M A, Nilsson K Lysozyme synthesis by established human and murine histiocytic lymphoma cell lines. J Exp Med 1976 143:1528-33 PubMed ID: 1083890 DOI: 10.1084/jem.143.6.1528

31 Röllinghoff M, Warner NL. Specificity of in vivo tumor rejection assessed by mixing immune spleen cells with target and unrelated tumor cells Proc Soc Exp Biol Med 1973 144(3):813-8 PubMed ID: 4543620 DOI: 10.3181/00379727-144-37688

126 Rouse BT, Röllinghoff M, Warner NL. Tumor immunity to murine plasma cell tumors. II. Essential role of T lymphocytes in immune response Eur J Immunol 1973 3(4):218-24 PubMed ID: 4541468 DOI: 10.1002/eji.1830030408

5289 Metcalf D, Moore MA, Warner NL. Colony formation in vitro by myelomonocytic leukemic cells. J Natl Cancer Inst 1969 43(4):983-1001 PubMed ID: 5259326

84 Warner NL, Moore MA, Metcalf D. A transplantable myelomonocytic leukemia in BALB-c mice: cytology, karyotype, and muramidase content J Natl Cancer Inst 1969 43(4):963-8 PubMed ID: 5259325

Top

User's Publication

21235 Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung Cancer. Clin Cancer Res 2023 PubMed ID: 37249619 DOI: 10.1158/1078-0432.CCR-22-3901

16770 Fujino T, Suda K, Koga T, Hamada A, Ohara S, Chiba M, Shimoji M, Takemoto T, Soh J, Mitsudomi T. Foretinib can overcome common on-target resistance mutations after capmatinib/tepotinib treatment in NSCLCs with MET exon 14 skipping mutation J Hematol Oncol 2022 15(1):79 PubMed ID: 35690785 DOI: 10.1186/s13045-022-01299-z

17935 Saito Y, Koya J, Araki M, Kogure Y, Shingaki S, Tabata M, McClure MB, Yoshifuji K, Matsumoto S, Isaka Y, Tanaka H, Kanai T, Miyano S, Shiraishi Y, Okuno Y, Kataoka K. Landscape and function of multiple mutations within individual oncogenes Nature 2020 582(7810):95-99 PubMed ID: 32494066 DOI: 10.1038/s41586-020-2175-2

11561 Yamada R, Fukumoto R, Noyama C, Fujisawa A, Oka S, Imamura T. An epidermis-permeable dipeptide is a potential cosmetic ingredient with partial agonist/antagonist activity toward fibroblast growth factor receptors. J Cosmet Dermatol 2020 19(2):477-484 PubMed ID: 31099492 DOI: 10.1111/jocd.12997

11622 Fujino T, Kobayashi Y, Suda K, Koga T, Nishino M, Ohara S, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro. J Thorac Oncol 2019 14(10):1753-1765 PubMed ID: 31279006 DOI: 10.1016/j.jtho.2019.06.023

17202 Elbadry MI, Mizumaki H, Hosokawa K, Espinoza JL, Nakagawa N, Chonabayashi K, Yoshida Y, Katagiri T, Hosomichi K, Zaimoku Y, Imi T, Nguyen MAT, Fujii Y, Tajima A, Ogawa S, Takenaka K, Akashi K, Nakao S. Escape hematopoiesis by HLA-B5401-lacking hematopoietic stem progenitor cells in men with acquired aplastic anemia Haematologica 2019 104(10):e447-e450 PubMed ID: 30890597 DOI: 10.3324/haematol.2018.210856

11331 Nishino M, Suda K, Kobayashi Y, Ohara S, Fujino T, Koga T, Chiba M, Shimoji M, Tomizawa K, Takemoto T, Mitsudomi T. Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitro. Lung Cancer 2018 PubMed ID: 30527179 DOI: 10.1016/j.lungcan.2018.10.026

4860 Ishibashi T, Yaguchi A, Terada K, Ueno-Yokohata H, Tomita O, Iijima K, Kobayashi K, Okita H, Fujimura J, Ohki K, Shimizu T, Kiyokawa N. Ph-like ALL-related novel fusion kinase ATF7IP-PDGFRB exhibits high sensitivity to tyrosine kinase inhibitors in murine cells. Exp Hematol 2016 44(3):177-88.e5 PubMed ID: 26703895 DOI: 10.1016/j.exphem.2015.11.009

14149 Shimizu K, Yamasaki S, Shinga J, Sato Y, Watanabe T, Ohara O, Kuzushima K, Yagita H, Komuro Y, Asakura M, Fujii S. Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells Cancer Res 2016 76(13):3756-66 PubMed ID: 27371739 DOI: 10.1158/0008-5472.CAN-15-3219

15120 Kobayashi Y, Togashi Y, Yatabe Y, Mizuuchi H, Jangchul P, Kondo C, Shimoji M, Sato K, Suda K, Tomizawa K, Takemoto T, Hida T, Nishio K, Mitsudomi T. EGFR Exon 18 Mutations in Lung Cancer: Molecular Predictors of Augmented Sensitivity to Afatinib or Neratinib as Compared with First- or Third-Generation TKIs Clin Cancer Res 2015 21(23):5305-13 PubMed ID: 26206867 DOI: 10.1158/1078-0432.CCR-15-1046

8857 Tao Y, Nomura M, Kitabatake N, Tani F. Mouse CD40-transfected cell lines cannot exhibit the binding and RANTES-stimulating activity of exogenous heat shock protein 70. Mol. Immunol. 2007 44:1262-73 PubMed ID: 16930707 DOI: 10.1016/j.molimm.2006.06.002

2559 Shimizu A, Tada K, Shukunami C, Hiraki Y, Kurokawa T, Magane N, Kurokawa-Seo M A novel alternatively spliced fibroblast growth factor receptor 3 isoform lacking the acid box domain is expressed during chondrogenic differentiation of ATDC5 cells. J Biol Chem 2001 276:11031-40 PubMed ID: 11134040 DOI: 10.1074/jbc.M003535200

2473 Tanaka I, Ishihara H Enhanced expression of the early retrotransposon in C3H mouse-derived myeloid leukemia cells. Virology 2001 280:107-14 PubMed ID: 11162824 DOI: 10.1006/viro.2000.0732

4871 Feng R, Kabayama A, Uchida K, Hoshino H, Miwa M. Cell-free entry of human T-cell leukemia virus type 1 to mouse cells. Jpn J Cancer Res 2001 92(4):410-6 PubMed ID: 11346463 DOI: 10.1111/j.1349-7006.2001.tb01110.x

16915 Sun W, Hattori N, Mutai H, Toyoshima Y, Kimura H, Tanaka S, Shiota K. PAL31, a nuclear protein required for progression to the S phase Biochem Biophys Res Commun 2001 280(4):1048-54 PubMed ID: 11162633 DOI: 10.1006/bbrc.2000.4244

2951 Yokota S, Kayano T, Ohta T, Kurimoto M, Yanagi H, Yura T, Kubota H Proteasome-dependent degradation of cytosolic chaperonin CCT Biochemical and biophysical research communications 2000 279:712-717 PubMed ID: 11118350 DOI: 10.1006/bbrc.2000.4011

2380 Yokota S, Yanagi H, Yura T, Kubota H Cytosolic chaperonin is up-regulated during cell growth. Preferential expression and binding to tubulin at G(1)/S transition through early S phase. J Biol Chem 1999 274:37070-8 PubMed ID: 10601265 DOI: 10.1074/jbc.274.52.37070

2215 Saneyoshi K, Nohara O, Imai T, Shiraishi F, Moriyama H, Fujimaki H IL-4 and IL-6 production of bone marrow-derived mast cells is enhanced by treatment with environmental pollutants. Int Arch Allergy Immunol 1997 114:237-45 PubMed ID: 9363904 DOI: 10.1159/000237674

18023 Ogasawara T, Murakami M, Suzuki-Nishimura T, Uchida MK, Kudo I. Mouse bone marrow-derived mast cells undergo exocytosis, prostanoid generation, and cytokine expression in response to G protein-activating polybasic compounds after coculture with fibroblasts in the presence of c-kit ligand J Immunol 1997 158(1):393-404 PubMed ID: 8977215

4830 Sasaki M, Sasaki T, Enami J. Prolactin-dependent growth and gamma-casein gene expression in Ba/F3 cells transfected with a long form of mouse mammary prolactin receptor. Endocr J 1996 43(1):45-52 PubMed ID: 8732451 DOI: 10.1507/endocrj.43.45

2216 Fujimaki H, Nohara O, Katayama N, Abe T, Nohara K Ganglioside GM3 inhibits interleukin-3-dependent bone marrow-derived mast cell proliferation. Int Arch Allergy Immunol 1995 107:527-32 PubMed ID: 7620368 DOI: 10.1159/000237095

5411 Nakamura M, Sakanaka C, Aoki Y, Ogasawara H, Tsuji T, Kodama H, Matsumoto T, Shimizu T, Noma M. Identification of two isoforms of mouse neuropeptide Y-Y1 receptor generated by alternative splicing. Isolation, genomic structure, and functional expression of the receptors. J Biol Chem 1995 270(50):30102-10 PubMed ID: 8530415 DOI: 10.1074/jbc.270.50.30102

1730 Katayama, N., Honda, Y. and Fujimaki, H. Growth and Functional Modifications in Formaldehyde-Treated Mouse Bone Marrow-Derived Mast Cells Toxicol in Vitro 1992 6:239-243 PubMed ID: 20732119 DOI: 10.1016/0887-2333(92)90037-r

1731 Fujimaki H, Kawagoe A, Bissonnette E, Befus D Mast cell response to formaldehyde. 1. Modulation of mediator release. Int Arch Allergy Immunol 1992 98:324-31 PubMed ID: 1384864 DOI: 10.1159/000236206